International Journal of Clinical Case Reports 2024, Vol.14, No.1, 55-62 http://medscipublisher.com/index.php/ijccr 55 Research Article Open Access The Impact of Drug Metabolism Enzyme Gene Polymorphism on Drug Response Yangjie Zhong Zhejiang Zhuji Medical Materials Co., Ltd, Zhuji, 311800, China Corresponding email: 2314548193@qq.com International Journal of Clinical Case Reports 2024, Vol.14, No.1 doi: 10.5376/ijccr.2024.14.0007 Received: 12 Mar., 2024 Accepted: 13 Apr., 2024 Published: 24 Apr., 2024 Copyright © 2024 Zhong, This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Preferred citation for this article: Zhong Y.J., 2024, The impact of drug metabolism enzyme gene polymorphism on drug response, International Journal of Clinical Case Reports, 14(1): 55-62 (doi: 10.5376/ijccr.2024.14.0007) Abstract The genetic polymorphism of drug metabolism enzymes is a highly concerned research direction in the field of drug therapy, and has made significant progress in medicine and clinical practice. The polymorphism of drug metabolism enzyme genes has broad clinical importance for drug response, and its research goal is to understand how patient genotype information shapes their response to specific drugs, so that doctors can better formulate personalized treatment plans. This not only helps to improve the safety and success rate of patients' treatment, but also provides important clues for the development of new drugs to create safer and more effective treatment methods, further promoting the development of the medical field. This study provides an in-depth understanding of how genetic polymorphisms affect individuals' metabolic rate of drugs and the individualization of drug therapy. It explores the close relationship between phenotypic polymorphisms and drug response, and combines specific case studies of drug therapy to provide new insights into improving medical outcomes. Keywords Drug metabolizing enzymes; Genetic polymorphism; Drug response; Personalized medicine; Case study In modern medicine, personalized therapy has gradually become a highly focused area of research. Individualization of drug therapy refers to tailoring the most suitable treatment plan for patients based on their genotype and phenotype characteristics. The polymorphism of drug-metabolizing enzyme genes, as a crucial aspect of individual differences, has drawn considerable attention from researchers and clinicians. Drug-metabolizing enzyme gene polymorphism refers to the occurrence of different genotypes among individuals, and these distinct genotypes can influence the expression and activity of drug-metabolizing enzymes. Drug-metabolizing enzymes are proteins that mediate the metabolism and degradation of drugs in the body, including the cytochrome P450 (CYP) family, uridine diphosphate-glucuronosyltransferase (UGT) family, and N-acetyltransferase (NAT) family, among others. The function of these metabolic enzymes is to convert drugs into active metabolites or inactive metabolites, thereby affecting the efficacy and toxicity of drugs (Xu et al., 2018). Differences in drug-metabolizing enzyme genotypes among individuals can result in significant variations in drug effects. Some individuals may metabolize a certain drug more rapidly due to their genotype, requiring higher doses to achieve therapeutic effects. On the other hand, other individuals may metabolize the same drug more slowly due to their genotype, leading to drug accumulation and adverse reactions. Therefore, understanding an individual's drug-metabolizing enzyme genotype is of crucial importance. Doctors can select appropriate drugs and adjust dosages based on the patient's genetic characteristics to ensure the safety and effectiveness of treatment. This personalized approach can maximize the success rate of drug therapy while minimizing unnecessary risks and adverse reactions (Dev et al., 2019). The importance of studying drug-metabolizing enzyme gene polymorphism lies in its ability to provide clinicians with powerful tools to better predict patients' responses to specific drugs. This aids in reducing unnecessary adverse drug reactions, enhancing treatment success rates, and saving healthcare resources. Additionally, understanding drug-metabolizing enzyme gene polymorphism provides crucial insights for the development and design of drugs, enabling the creation of safer and more effective medications. By optimizing the structure and
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==